Evidence map›Paper›PMID 32448180›Full record

ArticleBMC nephrology2020

IgM monoclonal gammopathy with heavy-and-light-chain amyloidosis resembling fibrillary glomerulonephritis determined by tandem mass spectrometry: a case report.

Misa Adachi, Mineaki Kitamura, Kumiko Muta, Akihiro Maekawa, Tadashi Uramatsu, Masato Tadokoro, Satoshi Funakoshi, Satoshi Hisano, Naomi Kuwahara, Akira Shimizu and 2 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Misa AdachiDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Mineaki KitamuraDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. minekitamura@nagasaki-u.ac.jp.ORCID 0000-0002-0003-8645
Kumiko MutaDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Akihiro MaekawaDepartment of Nephrology, Nagasaki Medical Center, Omura, Japan.
Tadashi UramatsuDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masato TadokoroDepartment of Nephrology, Koritsu Shin-Obama Hospital, Nagasaki, Japan.
Satoshi FunakoshiDepartment of Nephrology, Nagasaki Renal Center, Nagasaki, Japan.
Satoshi HisanoDepartment of Pathology, University of Occupational and Environmental Health School of Medicine, Kitakyushu, Japan.
Naomi KuwaharaDepartment of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Akira ShimizuDepartment of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Tomoya NishinoDepartment of Nephrology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Nagasaki University · JPNagasaki Medical Center · JPNippon Medical School · JPUniversity of Nagasaki · JPUniversity of Occupational and Environmental Health Japan · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFibrillary glomerulonephritis (FGN) is distinguished from amyloidosis by thicker fibrils and the lack of staining with histochemical dyes typically reactive with amyloid. However, congophilic FGN has been proposed recently and adding laser microdissection followed by mass spectrometry (LMD/MS) to conventional pathological methods would be helpful to diagnose FGN. Here, we report a patient initially diagnosed with FGN whose final pathological diagnosis was changed to immunoglobulin heavy-and-light-chain amyloidosis (AHL) after LMD/MS. CASE PRESENTATION: A 75-year-old male developed nephrotic syndrome. Protein electrophoresis showed IgM κ type M proteinemia and he was diagnosed with IgM monoclonal gammopathy. A renal biopsy was performed and pathological examination showed marked periodic acid-Schiff-positive enlargement of the mesangial region and silver stain positivity, but weak direct fast scarlet staining. Immunofluorescence analysis showed monoclonal deposition of IgM-κ chain in the glomerulus. Under electron microscopy, the fibrils were about 20 nm in diameter, which was thicker than typical amyloid fibrils. Based on these findings, the patient was diagnosed with FGN. Although cyclophosphamide and prednisolone were administered, his renal function deteriorated and progressed to end stage renal disease requiring maintenance hemodialysis. As congophilic FGN has been recognized since 2018, Congo red staining and LMD/MS were performed. The Congo red staining was positive and LMD/MS results indicated that this was a case of AHL.

conclusionsWe reported a case of μ and κ chain AHL resembling FGN requiring LMD/MS for definitive diagnosis. Since FGN and amyloidosis exhibit pathological findings, even if Congo red staining is positive, LMD/MS needs to be considered in cases atypical pathological findings, such as silver stain positivity or thicker fibrils.

Indexed as

AgedDiagnosis, DifferentialGlomerulonephritisHumansImmunoglobulin Heavy ChainsImmunoglobulin Light-chain AmyloidosisImmunoglobulin MMaleNephrotic SyndromeTandem Mass SpectrometryImmunoglobulin Heavy ChainsImmunoglobulin MFibrillary glomerulonephritisIgM gammopathyImmunoglobulin heavy-and-light-chain amyloidosisLaser micro dissectionMass spectrometry

Identifiers

PMID32448180
PMCPMC7245905
OpenAlexW3026923487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.